Cardiol Res

Cardiology Research, ISSN 1923-2829 print, 1923-2837 online, Open Access

Article copyright, the authors; Journal compilation copyright, Cardiol Res and Elmer Press Inc

Journal website https://www.cardiologyres.org

Original Article

Volume 12, Number 2, April 2021, pages 109-116

Platelet-to-Lymphocyte Ratio at Admission as a Predictor of In-Hospital and Long-Term Outcomes in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis

Figures

Figure 1. Literature search flow chart. PCI: percutaneous coronary intervention; STEMI: ST-segment elevation myocardial infarction.

Figure 2. Forest plots of the association between PLR at admission and in-hospital outcomes in STEMI patients undergoing primary PCI. (a) In-hospital MACE. (b) In-hospital mortality. PLR: platelet-to-lymphocyte ratio; PCI: percutaneous coronary intervention; MACE: major adverse cardiac event; STEMI: ST-segment elevation myocardial infarction; CI: confidence interval.

Figure 3. Forests plots of the association between PLR at admission and long-term outcomes in STEMI patients undergoing primary PCI. (a) Long-term MACE. (b) Long-term mortality. PLR: platelet-to-lymphocyte ratio; PCI: percutaneous coronary intervention; MACE: major adverse cardiac event; STEMI: ST-segment elevation myocardial infarction; CI: confidence interval.

Figure 4. Funnel plots of the association between PLR at admission and in-hospital outcomes in STEMI patients undergoing primary PCI. (a) In-hospital MACE. (b) In-hospital mortality. PLR: platelet-to-lymphocyte ratio; PCI: percutaneous coronary intervention; MACE: major adverse cardiac event; STEMI: ST-segment elevation myocardial infarction.

Tables

**Table 1.** Characteristics of the Studies Included in the Meta-Analysis
Study, year	Country	Design	Sample size	Age (years)	Male (%)	Follow-up duration	PLR cut-off	Outcomes
PLR: platelet-to-lymphocyte ratio; RC: retrospective cohort; PC: prospective cohort; MACE: major adverse cardiac events.
Ayca et al, 2014 [20]	Turkey	RC	440	56	67	During hospitalization	137	In-hospital MACE, in-hospital mortality
Ugur et al, 2014 [21]	Turkey	PC	639	56	85	6 months	175	In-hospital MACE, in-hospital mortality, long-term MACE, long-term mortality
Cetin et al, 2015 [22]	Turkey	PC	1,938	60	66	32 months	147	In-hospital MACE, in-hospital mortality, long-term MACE, long-term mortality
Toprak et al, 2015 [23]	Turkey	PC	304	60	81	24 months	217	In-hospital MACE, in-hospital mortality, long-term MACE, long-term mortality
Hudzik et al, 2015 [24]	Poland	PC	523	64	41	12 months	124	In-hospital mortality, long-term mortality
Maimati et al, 2019 [25]	China	RC	445	61	65	During hospitalization	165	In-hospital MACE, in-hospital mortality

**Table 2.** Quality Assessment of the Included Studies by Newcastle-Ottawa Scale
Study, year	Selection	Comparability	Outcome	Total rating
Ayca et al, 2014 [20]	★★★★	★★	★★	8★
Ugur et al, 2014 [21]	★★★★	★★	★★★	9★
Cetin et al, 2015 [22]	★★★★	★★	★★★	9★
Toprak et al, 2015 [23]	★★★★	★★	★★★	9★
Hudzik et al, 2015 [24]	★★★★	★★	★★	8★
Maimati et al, 2019 [25]	★★★★	★★	★★	8★